ARGOS THERAPEUTICS INC
DelistedCIK 1105533fmd_1C4HTMF57E2QKV4VVEG5H2CPWDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2018, 25 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 7 | 4 | 2 | 1 | 1 | 2 |
| Research and development | – | 18 | 24 | 45 | 62 | 38 | 22 |
| Total operating expenses | – | 24 | 29 | 54 | 73 | 53 | 64 |
| Operating income | – | (17) | (24) | (52) | (73) | (52) | (62) |
| Interest expense | – | 0 | 0 | 1 | 2 | 2 | 1 |
| Interest and investment income | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | 6 | 0 | (1) | (2) | (1) | 22 |
| Income tax expense | 0 | 0 | – | 0 | 0 | 0 | 0 |
| Net income | – | (10) | (24) | (53) | (75) | (53) | (41) |
| Net income to common shareholders | – | (11) | (34) | (54) | (75) | (53) | – |